Section one: Contracting authority/entity
one.1) Name and addresses
NHS Wales Shared Services Partnership
Procurement Services, Cardiff and Vale University Local Health Board, Woodlands House, Maes-Y-Coed Road
Cardiff
CF14 4HH
Telephone
+44 02921836450
Country
United Kingdom
NUTS code
UK - United Kingdom
Internet address(es)
Main address
http://www.procurement.wales.nhs.uk
Buyer's address
http://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Purchase of Apheresis Spectra Optia machines with maintenance and consumables
Reference number
CAV-STA (22-23) 5
two.1.2) Main CPV code
- 33140000 - Medical consumables
two.1.3) Type of contract
Supplies
two.1.4) Short description
NHS Wales Shared Services Partnership who are hosted by Velindre NHS Trust acting on behalf of Cardiff and Vale University Local Health Board wish to inform the market that they intend to award a contract for the purchase of three Apheresis Spectra Optia machines with maintenance and consumables.
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £400,000
two.2) Description
two.2.2) Additional CPV code(s)
- 33194210 - Blood-transfusion devices
two.2.3) Place of performance
NUTS codes
- UKL22 - Cardiff and Vale of Glamorgan
two.2.4) Description of the procurement
The South Wales Blood and Marrow Transplant Programme (SWBMT) serves adults and children within the catchment area of mid, west and south Wales, comprising six of the seven Welsh Local Health Boards (LHBs), with a combined population of approximately 2.4 million and accounting for over three-quarters of the Welsh population.
The Children’s oncology unit at the Children’s Hospital for Wales (CHfW) is the only unit in Wales that provides treatment for children with complex haematological conditions (such as sickle cell anaemia or treatments requiring cell collection for re-infusion post chemotherapy). The unit works closely in partnership with the adult haematology department as the services are small and the processes required to manage the paediatric conditions are carried out rarely. Therefore education, training and maintaining competence are dependent on working in partnership with the adult service.
The three Spectra Optia machines required to carry out apheresis, cell collection or cell processing procedures in this speciality are now of an age where they require replacement. The machine carries out highly specialist processes so they have to be reliable and accurate.
This notice is for the purchase of three Spectra Optia machines including maintenance for up to five years (after the one year warranty) and consumables.
two.2.11) Information about options
Options: Yes
Description of options
Up to five years for maintenance (after the one year warranty) and consumables.
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Award of a contract without prior publication of a call for competition in the cases listed below
- The procurement falls outside the scope of application of the regulations
Explanation:
The apheresis service at Cardiff and Vale UHB provides:
1. Donor apheresis (collection of haematopoietic progenitor cells [HPC, A] and peripheral blood mononuclear cells for immediate therapeutic use as well as a precursor for manufacture into chimaeric antigen receptor (CAR) T-cells) [MNC, A]
2. Therapeutic apheresis including plasma exchange and red blood cell exchange
NICE Medical Technologies Guidance [MTG28], published the 2nd March 2016 and updated August 2020, concluded, inter alia, that the Spectra Optia is effective for managing red blood cell exchange in managing sickle cell disease and further noted that use of the Spectra Optia is likely to result in significant cost savings in most patients with sickle cell disease. NICE further noted that adopting the Spectra Optia is estimated to result in cost savings per person per year. As a result of this Guidance, NHSE has adopted the Spectra Optia system for its apheresis services.
Given the need to perform both donor and therapeutic apheresis, It is imperative that the chosen platform is able to perform both functions effectively and efficiently. The Spectra Optia is the only system to have been reviewed and approved by NICE [MTG28] for therapeutic red cell exchange with resultant savings to the NHS. This is a service provided to the Health Board's patient population with sickle cell disease.
In addition, the Paediatrics department requires the same equipment throughout the Health Board to align with Adult services ensuring standardised patient treatment and care along with staff training. Any change in equipment would mean that staff would require retraining and through the initial transition there is a greater risk of use error due to unfamiliarity.
On the above basis, the Health Board is issuing this notice and applying a 10 day standstill period prior to award of the purchase of three machines and a contract for up to five years for maintenance (after the one year warranty) and consumables.
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
Section five. Award of contract/concession
A contract/lot is awarded: Yes
five.2) Award of contract/concession
five.2.1) Date of conclusion of the contract
29 December 2022
five.2.2) Information about tenders
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor/concessionaire
Terumo BCT Ltd
Old Belfast , Millbrook
Larne
BT402SH
Country
United Kingdom
NUTS code
- UKN0 - Northern Ireland
The contractor/concessionaire is an SME
No
five.2.4) Information on value of contract/lot/concession (excluding VAT)
Total value of the contract/lot/concession: £400,000
Section six. Complementary information
six.3) Additional information
The value stated in this notice is the higher ceiling contract figure and may not be fully utilised as this will be dependent upon the volume of consumables ordered and maintenance years taken up.
(WA Ref:127796)
six.4) Procedures for review
six.4.1) Review body
High Court
London
Country
United Kingdom
Internet address
http://www.procurement.wales.nhs.uk
six.4.3) Review procedure
Precise information on deadline(s) for review procedures
NHS Wales Shared Services Partnership on behalf of Cardiff and Vale University Health Board will allow a minimum 10 calendar day standstill period between notifying the award decision and awarding the contract.